Companies › AOTI
1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Topical Wound Oxygen Therapy (TWO2) Cyclical topical oxygen pressure applied directly to wound site in sealed environment | – | Phase 4 | Venous Leg Ulcer (VLU) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06754735 | Topical Wound Oxygen Therapy (TWO2) | Phase 4 | Venous Leg Ulcer (VLU) | Cardiovascular | Jun 2027 |
No annotated target.
–
Cell Biopeutics Resources Sdn Bhd TR Therapeutics Kerecis Beijing Inno Medicine Nectero Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.